Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
- 1 February 2006
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 29 (2), 300-305
- https://doi.org/10.2337/diacare.29.02.06.dc05-1070
Abstract
OBJECTIVE—Evidence suggests that some actions of insulin are effected by inositolphosphoglycan (IPG) mediators. We hypothesize that a deficiency in D-chiro-inositol (DCI) and/or a DCI-containing IPG (DCI-IPG) may contribute to insulin resistance in humans. RESEARCH DESIGN AND METHODS—To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women. RESULTS—Women with PCOS were heavier than control subjects (P = 0.002 for BMI), but also had decreased Si (P < 0.001) and increased AUCinsulin (P < 0.001) compared with normal women, even when corrected for BMI. The urinary clearance of DCI (uClDCI) was increased almost sixfold in PCOS compared with normal women (P = 0.001), but not MYO clearance (P = 0.10). uClDCI correlated inversely with Si when all women were analyzed together (n = 49, r = −0.50, P < 0.001) and was one of the three best independent parameters predicting Si. Finally, the ratio of AUCDCI-IPG to AUCinsulin was decreased threefold in women with PCOS (P < 0.001). CONCLUSIONS—uClDCI is inversely correlated with insulin sensitivity in women and is a strong independent predictor of insulin resistance in multivariate models. PCOS, which is characterized by insulin resistance, is associated with a selective increase in uClDCI and impaired DCI-IPG release in response to insulin. These findings are consistent with a defect in tissue availability or utilization of DCI in PCOS that may contribute to the insulin resistance of the syndrome.This publication has 31 references indexed in Scilit:
- Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndromeCurrent Opinion in Endocrinology, Diabetes and Obesity, 2002
- A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic ProfileJournal of Clinical Endocrinology & Metabolism, 1999
- Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary SyndromeThe New England Journal of Medicine, 1999
- Role of Hyperinsulinemia in the Pathogenesis of the Polycystic Ovary Syndrome, and Its Clinical ImplicationsSeminars in Reproductive Medicine, 1997
- Urinary chiro-Inositol Excretion is an Index Marker of Insulin Sensitivity in Japanese Type II DiabetesDiabetes Care, 1994
- Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic menJournal of Clinical Endocrinology & Metabolism, 1994
- Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approachDiabetes, 1989
- Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndromeDiabetes, 1989
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureJournal of Steroid Biochemistry, 1982
- Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.JCI Insight, 1981